Targeting metastatic melanoma.

  title={Targeting metastatic melanoma.},
  author={Jamie Poust},
  journal={American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists},
  volume={65 24 Suppl 9},
  • Jamie Poust
  • Published 15 December 2008
  • Biology, Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
PURPOSE New medications and combination treatment strategies for patients with metastatic melanoma are discussed. SUMMARY Bcl-2 is an inhibitor of apoptosis that is overexpressed in approximately 80% of melanoma cell lines and is believed to contribute to the development of resistance to cytotoxic chemotherapy in patients with melanoma. Oblimersen, an antisense oligonucleotide that stops the translation of Bcl-2 mRNA to protein, significantly improved progression-free survival when… 

Figures from this paper

Immune Checkpoint Inhibitors: Therapeutic Tools for Breast Cancer.
The potential of certain inhibitors of immune checkpoints, such as antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1) and lymphocyte activation gene-3 (LAG-3), in breast cancer therapeutics are discussed.
Combined Effects of Capsaicin and HA14-1 in Inducing Apoptosis in Melanoma Cells
A comparative study showed that melanoma cells and melanocytes have a similar sensitivity to capsaicin while fibroblasts are more resistant to it, and a combination of the two drugs showed a synergistic induction of apoptosis.
Beyond immune checkpoint blockade: emerging immunological strategies.
The critical aspects - beyond T cell co-receptors - of immune processes within the tumour microenvironment (TME) that may serve as avenues along which new therapeutic strategies in immuno-oncology can be forged are discussed.
Circulating serologic and molecular biomarkers in malignant melanoma.
Using the PubMed database, a synopsis of the extensive investigations that have been performed on serologic melanoma biomarkers are presented, some insight is provided into why most have failed to become incorporated into routine clinical use, and an overview of innovative methods currently being explored are presented.
Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH
This study encapsulates the evidence, as a possible strategy, to improve the efficacy of ICB-therapy by co-targeting molecular checkpoints especially N6A-modification machineries which can be reformed into RNA modifying drugs (RMD).
Widespread expressions of immunoglobulin superfamily proteins in cancer cells
It was hypothesized that the expressions of these immunoglobulin superfamily (IgSF) proteins may be relevant to the immune protection and proliferations of cancer cells during carcinogenesis or cancer progression and may be the potential targets for RP215-based anti-cancer drugs.
New Frontiers in Treatment
Patients experiencing advanced stage castration-resistant prostate cancer (CRPC) are at increased risk of developing skeletal-related events, including pathologic fractures and spinal cord compression.
An uncommon cause of epigastric pain and emesis.
A 35-year-old man presented to the gastrointestinal clinic with a 4-week history of sudden onset emesis and upper abdominal pain in the right epigastrium and multiple nodular polypoid dark lesions of the esophagus and gastric antrum and corpus were revealed.


Novel treatment strategies for malignant melanoma: a new beginning?
Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
A growing body of preclinical and clinical evidence suggests that oblimersen synergizes with many cytotoxic and biologic/immunotherapeutic agents against a variety of hematologic malignancies and solid tumors.
The role of B-RAF in melanoma
The B-RAF isoform, a family of serine/threonine-specific protein kinases that form part of a signalling module that regulates cell proliferation, differentiation and survival, is reviewed.
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
  • A. Bedikian, M. Millward, F. Haluska
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
The addition of oblimersen to dacarbazine significantly improved multiple clinical outcomes in patients with advanced melanoma and increased overall survival in patients without an elevated baseline serum LDH.
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
It is failed to find any clear evidence that the addition of immunotherapy to chemotherapy increases survival of people with metastatic melanoma, and increased hematological and non-hematological toxicities in people treated with chemoimmunotherapy.
Adjuvant therapy of malignant melanoma.
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
  • P. Attia, G. Phan, S. Rosenberg
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
Administration of anti-CTLA-4 monoclonal antibody plus peptide vaccination can cause durable objective responses, which correlate with the induction of autoimmunity, in patients with metastatic melanoma.
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
  • G. Phan, J. Yang, S. Rosenberg
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2003
This study establishes CTLA-4 as an important molecule regulating tolerance to “self” antigens in humans and suggests a role for CTla-4 blockade in breaking tolerance to human cancer antIGens for cancer immunotherapy.
Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas
The study suggests that BRAF mutation may be acquired during development of metastasis but is not a significant factor for primary tumor development and disease outcome.
Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
There is not evidence to support a synergistic effect of CTLA-4 blockade plus IL-2 administration, because the 22% objective response rate is that expected from the sum of these two agents administered alone.